Literature DB >> 392003

A relaxation technique in the management of hypercholesterolemia.

M J Cooper, M M Aygen.   

Abstract

Chronic sympathetic nervous system overactivity has been implicated as a factor capable of elevating and maintaining high serum cholesterol levels independent of dietary measures. We conducted a controlled trial to determine the effect of a relaxation technique. Transcendental Meditation, on serum cholesterol levels in hypercholesterolemic subjects. Serum cholesterol levels were measured at beginning and end of an 11-month period in 12 hypercholesterolemic subjects who regularly practiced meditation. Eleven hypercholesterolemic controls who did not practice the technique were similarly followed up for 13 months. Paired comparisons showed a significant (p less than 0.005) reduction in fasting serum cholesterol levels of those subjects who practiced meditation. These results suggest that the regular practice of a relaxation technique may contribute, most likely through a reduction in adrenergic activity, to the amelioration of hypercholesterolemia in certain subjects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 392003     DOI: 10.1080/0097840x.1979.10545991

Source DB:  PubMed          Journal:  J Human Stress        ISSN: 0097-840X


  13 in total

Review 1.  Review of controlled research on the transcendental meditation program and cardiovascular disease. Risk factors, morbidity, and mortality.

Authors:  Kenneth G Walton; Robert H Schneider; Sanford Nidich
Journal:  Cardiol Rev       Date:  2004 Sep-Oct       Impact factor: 2.644

Review 2.  Meditation and coronary heart disease: a review of the current clinical evidence.

Authors:  Indranill Basu Ray; Arthur R Menezes; Pavan Malur; Aimee E Hiltbold; John P Reilly; Carl J Lavie
Journal:  Ochsner J       Date:  2014

3.  Clinical and Pre-clinical Applications of the Transcendental Meditation Program in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults.

Authors:  Vernon A Barnes; David W Orme-Johnson
Journal:  Curr Hypertens Rev       Date:  2006-08-01

Review 4.  Cardiovascular disease prevention and health promotion with the transcendental meditation program and Maharishi consciousness-based health care.

Authors:  Robert H Schneider; Kenneth G Walton; John W Salerno; Sanford I Nidich
Journal:  Ethn Dis       Date:  2006       Impact factor: 1.847

Review 5.  WITHDRAWN: Transcendental meditation for the primary prevention of cardiovascular disease.

Authors:  Louise Hartley; Angelique Mavrodaris; Nadine Flowers; Edzard Ernst; Karen Rees
Journal:  Cochrane Database Syst Rev       Date:  2017-11-15

6.  Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation(®) Program: A Research Review Update.

Authors:  Vernon A Barnes; David W Orme-Johnson
Journal:  Curr Hypertens Rev       Date:  2012-08

7.  Elevated serum dehydroepiandrosterone sulfate levels in practitioners of the Transcendental Meditation (TM) and TM-Sidhi programs.

Authors:  J L Glaser; J L Brind; J H Vogelman; M J Eisner; M C Dillbeck; R K Wallace; D Chopra; N Orentreich
Journal:  J Behav Med       Date:  1992-08

Review 8.  Psychosocial stress and cardiovascular disease Part 2: effectiveness of the Transcendental Meditation program in treatment and prevention.

Authors:  Kenneth G Walton; Robert H Schneider; Sanford I Nidich; John W Salerno; Cheryl K Nordstrom; C Noel Bairey Merz
Journal:  Behav Med       Date:  2002       Impact factor: 3.104

9.  Inability to demonstrate physiologic correlates of subjective improvement among patients taught the relaxation response.

Authors:  D M Eisenberg; L Landsberg; E N Allred; R B Saper; T L Delbanco
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

Review 10.  Awakening is not a metaphor: the effects of Buddhist meditation practices on basic wakefulness.

Authors:  Willoughby B Britton; Jared R Lindahl; B Rael Cahn; Jake H Davis; Roberta E Goldman
Journal:  Ann N Y Acad Sci       Date:  2013-12-26       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.